Grifols is taking another step forward in Alzheimer research. The Catalan biotech group, a CataloniaBio & HealthTech member, and Ace Alzheimer Center are opening the first Ambar Center in Barcelona to collect data from standard clinical practice in Alzheimer.
The Ambar Center will be located at the Ace facility and managed by its medical professionals.
Grifols’ Ambar programme is based on daily plasma exchange with albumin. The procedure has been proven to delay cognitive and functional progression in mild-to-moderate Alzheimer patients in a Phase IIB/III clinical trial.
“The goal is to get data to complement the results of the clinical study as a step prior to commercialising this therapy,” explained Antonio Páez, Grifols medical director of the Ambar clinical programme.
Grifols plans to open more Ambar Centers in Europe, the United States and China.
Photo: Mercè Boada, co-founder of Ace, and Antonio Páez, Medical Director Grifols’ Ambar programme.
Comments